Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3mg/m2 with 6mg/m2 in the NCRI AML17 trial

Alan Burnett, Jamie Cavenagh, Nigel Russell, Robert Hills, Jonathan Kell, Gail Jones, Ove Juul Nielsen, Asim Khwaja, Ian Thomas, and Richard Clark

Disclosures: We are grateful to Cancer Research UK for research funding for this trial and to Pfizer Japan for supplying Gemtuzumab Ozogamicin at a discounted price, to the staff of the Haematology Trials Office and Cardiff Experimental Cancer Medicine Centre for supporting the trial and to our co-investigators. AKB, RKH have served on advisory boards for Pfizer.

Contributions: AKB devised the study/ wrote the protocol and manuscript, and acted as chief investigator, undertook the analysis; JC recruited the largest number of patients and reviewed the manuscript NHR Acted as chief Investigator and reviewed the manuscript; RKH devised the trial, ran the trial office, performed the analysis and reviewed the manuscript; JK undertook the VOD reviews, recruited patients and reviewed the manuscript; GJ recruited patients and reviewed the manuscript; OJN recruited patients and reviewed the manuscript; AK recruited patients and reviewed the manuscript; IFT supervised the data collection; REC recruited patients and reviewed the manuscript.